These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34661106)

  • 1. Presumed small vessel disease, imaging and cognition markers in the Alzheimer's Disease Neuroimaging Initiative.
    Fiford CM; Sudre CH; Young AL; Macdougall A; Nicholas J; Manning EN; Malone IB; Walsh P; Goodkin O; Pemberton HG; Barkhof F; Alexander DC; Cardoso MJ; Biessels GJ; Barnes J;
    Brain Commun; 2021; 3(4):fcab226. PubMed ID: 34661106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease genetic risk and changes in brain atrophy and white matter hyperintensities in cognitively unimpaired adults.
    Soldan A; Wang J; Pettigrew C; Davatzikos C; Erus G; Hohman TJ; Dumitrescu L; Bilgel M; Resnick SM; Rivera-Rivera LA; Langhough R; Johnson SC; Benzinger T; Morris JC; Laws SM; Fripp J; Masters CL; Albert MS
    Brain Commun; 2024; 6(5):fcae276. PubMed ID: 39229494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer's Coordinating Center Uniform Data Set.
    Puzo C; Labriola C; Sugarman MA; Tripodis Y; Martin B; Palmisano JN; Steinberg EG; Stein TD; Kowall NW; McKee AC; Mez J; Killiany RJ; Stern RA; Alosco ML
    Alzheimers Res Ther; 2019 Jul; 11(1):64. PubMed ID: 31351489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrovascular disease promotes tau pathology in Alzheimer's disease.
    Laing KK; Simoes S; Baena-Caldas GP; Lao PJ; Kothiya M; Igwe KC; Chesebro AG; Houck AL; Pedraza L; Hernández AI; Li J; Zimmerman ME; Luchsinger JA; Barone FC; Moreno H; Brickman AM;
    Brain Commun; 2020; 2(2):fcaa132. PubMed ID: 33215083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polygenic coronary artery disease association with brain atrophy in the cognitively impaired.
    de Silva E; Sudre CH; Barnes J; Scelsi MA; Altmann A;
    Brain Commun; 2022; 4(6):fcac314. PubMed ID: 36523268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Entorhinal Perfusion Predicts Future Memory Decline, Neurodegeneration, and White Matter Hyperintensity Progression in Older Adults.
    Bangen KJ; Thomas KR; Sanchez DL; Edmonds EC; Weigand AJ; Delano-Wood L; Bondi MW;
    J Alzheimers Dis; 2021; 81(4):1711-1725. PubMed ID: 33967041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition.
    Vemuri P; Weigand SD; Przybelski SA; Knopman DS; Smith GE; Trojanowski JQ; Shaw LM; Decarli CS; Carmichael O; Bernstein MA; Aisen PS; Weiner M; Petersen RC; Jack CR;
    Brain; 2011 May; 134(Pt 5):1479-92. PubMed ID: 21478184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disentangling the effects of Alzheimer's and small vessel disease on white matter fibre tracts.
    Dewenter A; Jacob MA; Cai M; Gesierich B; Hager P; Kopczak A; Biel D; Ewers M; Tuladhar AM; de Leeuw FE; Dichgans M; Franzmeier N; Duering M;
    Brain; 2023 Feb; 146(2):678-689. PubMed ID: 35859352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A longitudinal magnetic resonance imaging study of neurodegenerative and small vessel disease, and clinical cognitive trajectories in non demented patients with transient ischemic attack: the PREVENT study.
    Tariq S; d'Esterre CD; Sajobi TT; Smith EE; Longman RS; Frayne R; Coutts SB; Forkert ND; Barber PA
    BMC Geriatr; 2018 Jul; 18(1):163. PubMed ID: 30012102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal patterns of leukoaraiosis and brain atrophy in symptomatic small vessel disease.
    Lambert C; Benjamin P; Zeestraten E; Lawrence AJ; Barrick TR; Markus HS
    Brain; 2016 Apr; 139(Pt 4):1136-51. PubMed ID: 26936939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrovascular and Alzheimer's disease biomarkers in dementia with Lewy bodies and other dementias.
    Rennie A; Ekman U; Shams S; Rydén L; Samuelsson J; Zettergren A; Kern S; Oppedal K; Blanc F; Hort J; Garcia-Ptacek S; Antonini A; Lemstra AW; Padovani A; Kramberger MG; Rektorová I; Walker Z; Snædal J; Pardini M; Taylor JP; Bonanni L; Granberg T; Aarsland D; Skoog I; Wahlund LO; Kivipelto M; Westman E; Ferreira D
    Brain Commun; 2024; 6(5):fcae290. PubMed ID: 39291165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife.
    Racine AM; Koscik RL; Berman SE; Nicholas CR; Clark LR; Okonkwo OC; Rowley HA; Asthana S; Bendlin BB; Blennow K; Zetterberg H; Gleason CE; Carlsson CM; Johnson SC
    Brain; 2016 Aug; 139(Pt 8):2261-74. PubMed ID: 27324877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Automated White Matter Hyperintensity Segmentation Using Bayesian Model Selection: Assessment and Correlations with Cognitive Change.
    Fiford CM; Sudre CH; Pemberton H; Walsh P; Manning E; Malone IB; Nicholas J; Bouvy WH; Carmichael OT; Biessels GJ; Cardoso MJ; Barnes J;
    Neuroinformatics; 2020 Jun; 18(3):429-449. PubMed ID: 32062817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting aggressive decline in mild cognitive impairment: the importance of white matter hyperintensities.
    Tosto G; Zimmerman ME; Carmichael OT; Brickman AM;
    JAMA Neurol; 2014 Jul; 71(7):872-7. PubMed ID: 24821476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer's Disease.
    Kellar D; Lockhart SN; Aisen P; Raman R; Rissman RA; Brewer J; Craft S
    J Prev Alzheimers Dis; 2021; 8(3):240-248. PubMed ID: 34101779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlating Cognitive Decline with White Matter Lesion and Brain Atrophy Magnetic Resonance Imaging Measurements in Alzheimer's Disease.
    Bilello M; Doshi J; Nabavizadeh SA; Toledo JB; Erus G; Xie SX; Trojanowski JQ; Han X; Davatzikos C
    J Alzheimers Dis; 2015; 48(4):987-94. PubMed ID: 26402108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APOE4 carrier status determines association between white matter disease and grey matter atrophy in early-stage dementia.
    Vipin A; Kumar D; Soo SA; Zailan FZ; Leow YJ; Koh CL; Ng ASL; Ng KP; Kandiah N
    Alzheimers Res Ther; 2023 Jun; 15(1):103. PubMed ID: 37270543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Particulate matter and episodic memory decline mediated by early neuroanatomic biomarkers of Alzheimer's disease.
    Younan D; Petkus AJ; Widaman KF; Wang X; Casanova R; Espeland MA; Gatz M; Henderson VW; Manson JE; Rapp SR; Sachs BC; Serre ML; Gaussoin SA; Barnard R; Saldana S; Vizuete W; Beavers DP; Salinas JA; Chui HC; Resnick SM; Shumaker SA; Chen JC
    Brain; 2020 Jan; 143(1):289-302. PubMed ID: 31746986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment.
    Lombardi G; Crescioli G; Cavedo E; Lucenteforte E; Casazza G; Bellatorre AG; Lista C; Costantino G; Frisoni G; Virgili G; Filippini G
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009628. PubMed ID: 32119112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subjective Cognitive Decline Is Associated with Greater White Matter Hyperintensity Volume.
    van Rooden S; van den Berg-Huysmans AA; Croll PH; Labadie G; Hayes JM; Viviano R; van der Grond J; Rombouts SARB; Damoiseaux JS
    J Alzheimers Dis; 2018; 66(3):1283-1294. PubMed ID: 30412485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.